| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
Lysine-specific demethylase 1 (LSD1) inhibitors are promising as a new type of anti-cancer drug. In this study, we aimed to develop novel anti-cancer drugs by fusing LSD1 inhibitor to pyrrole-imidazole polyamides (PIP), which are small molecules that can recognize DNA sequences, in order to enhance efficiency of LSD1 inhibitors.
In the cancer cells treated with the LSD1 inhibitor alone, the genomic regions with GC-rich sequence were the main target. In other hands, AT-rich regions were targetable by PIP-LSD1 inhibitor that binds to the AT-rich DNA sequence. These results suggest that a fusion with PIP could be a new epigenome-regulating anti-cancer drug.
|
